✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Bafna Pharmaceuticals Ltd.

BAFNAPH

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹407 Cr.
P/E
49.22

Bafna Pharmaceuticals Ltd.

  • Bafna Pharma
  • Medicamen Biotech
  • Medico Remedies
FAQs on Bafna Pharmaceuticals Ltd. Shareprice

Bafna Pharma has given better returns compared to its competitors.
Bafna Pharma has grown at ~102.73% over the last 1yrs while peers have grown at a median rate of -20.0%

Bafna Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Bafna Pharma is 49.22, while 3 year average PE is 94.42.
Also latest EV/EBITDA of Bafna Pharma is 28.72 while 3yr average is 25.66.

View FAQ's On Business
Growth Table
  • Bafna Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Medico Remedies
Balance Sheet
  • Bafna Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Medico Remedies
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Bafna Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Medico Remedies
Cash Flow
  • Bafna Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Medico Remedies
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Bafna Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Medico Remedies
Quarterly Results
  • Bafna Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Medico Remedies
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Bafna Pharmaceuticals Ltd. Financials

Balance sheet of Bafna Pharma is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Bafna Pharma is decreasing.
Latest net debt of Bafna Pharma is ₹21.34 Crs as of Mar-25.
This is less than Mar-24 when it was ₹21.6 Crs.

The profit is oscillating.
The profit of Bafna Pharma is ₹8.27 Crs for TTM, ₹4.15 Crs for Mar 2025 and ₹7.35 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Bafna Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech